Holen Sie sich die Stockscreener-App
1.27
0.78%
-0.01
Schlusskurs vom Vortag:
$1.28
Offen:
$1.27
24-Stunden-Volumen:
376.17K
Relative Volume:
0.73
Marktkapitalisierung:
$44.20M
Einnahmen:
$2.91M
Nettoeinkommen (Verlust:
$-220.40M
KGV:
-0.3489
EPS:
-3.64
Netto-Cashflow:
$-176.15M
1W Leistung:
-5.93%
1M Leistung:
+8.55%
6M Leistung:
-25.29%
1J Leistung:
-87.68%
1-Tages-Spanne:
$1.26
$1.28
1-Wochen-Bereich:
$1.26
$1.36
52-Wochen-Spanne:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Firmenname
Igm Biosciences Inc
Sektor
Branche
Telefon
650-965-7873
Adresse
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Vergleichen Sie IGMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.27 | 81.26M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-01-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-01-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-01-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-01-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-10-01 | Herabstufung | Truist | Buy → Hold |
| 2024-02-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-09 | Fortgesetzt | Jefferies | Buy |
| 2022-10-17 | Eingeleitet | JP Morgan | Neutral |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2021-12-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-01-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-07-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-07-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-28 | Eingeleitet | SunTrust | Buy |
| 2020-04-22 | Eingeleitet | Wedbush | Outperform |
| 2019-10-14 | Eingeleitet | Guggenheim | Buy |
| 2019-10-14 | Eingeleitet | Jefferies | Buy |
| 2019-10-14 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-10-14 | Eingeleitet | Stifel | Buy |
Alle ansehen
Igm Biosciences Inc Aktie (IGMS) Neueste Nachrichten
What analysts say about IGM Biosciences Inc. stockRapid-fire capital growth - jammulinksnews.com
Is IGM Biosciences Inc. a good long term investmentConsistently exceptional gains - jammulinksnews.com
Stockholder Sues IGM Biosciences for Alleged SEC Violations - Bloomberg Law News
IGM Biosciences Inc. Stock Analysis and ForecastLightning-fast growth - Autocar Professional
IGM Biosciences (NASDAQ:IGMS) Stock Price Down 5.9%Here's What Happened - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Reduce” from Brokerages - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
What drives IGM Biosciences Inc. stock priceConsistently exceptional gains - jammulinksnews.com
Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech
IGM Biosciences (NASDAQ:IGMS) Trading Down 5.9% – Here’s Why - Defense World
Why IGM Biosciences Inc. stock attracts strong analyst attentionConsistent High Return Strategy - beatles.ru
Concentra Group (CON) to Acquire IGM Biosciences - MSN
What makes IGM Biosciences Inc. stock price move sharplyFree Stock Market Real-Time Monitoring - Newser
How IGM Biosciences Inc. stock performs during market volatilityFree Access to Group - Newser
In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal - insights.citeline.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: GMS, IGMS, MRC, and GRYP - The Malaysian Reserve
IGM Biosciences to be acquired by Concentra - The Pharma Letter
Regeneron bispecific approved for myeloma; Concentra to buy IGM - BioPharma Dive
Concentra to acquire IGM Biosciences for $1.247 per share plus CVR - Investing.com Nigeria
Concentra Biosciences, LLC agreed to acquire IGM Biosciences, Inc. for $76.3 million. - MarketScreener
IGM Biosciences Shares Surge on Takeover Agreement with Concentra - MSN
IGM Biosciences Gets Snapped Up In Concentra Deal - Finimize
IGM Biosciences stock soars after Concentra acquisition deal - Investing.com
IGM Biosciences Enters Definitive Merger Agreement with Concentra Biosciences for Acquisition - Nasdaq
IGM Biosciences stock soars after Concentra acquisition deal By Investing.com - Investing.com UK
IGM Biosciences, Inc.(NasdaqGS: IGMS) dropped from Russell 3000 Index - MarketScreener
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Igm biosciences CFO Tahir Misbah sells $1,825 in stock - Investing.com
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
IGM Biosciences price target lowered to $1 from $2 at Truist - Yahoo Finance
IGM Biosciences Faces Nasdaq Non-Compliance Notice - TipRanks
Truist Revises IGM Biosciences (IGMS) Price Target to $1 | IGMS Stock News - GuruFocus
Truist Cuts Price Target on IGM Biosciences to $1 From $2, Keeps Hold Rating - MarketScreener
IGM Biosciences (NASDAQ:IGMS) Cut to "Sell" at Wall Street Zen - MarketBeat
Finanzdaten der Igm Biosciences Inc-Aktie (IGMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):